This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously and intraarticularly for the treatment of Osteoarthritis.
Studies have shown that stem cell treatment is safe and efficacious for the treatment of Osteoarthritis (OA). This patient funded trial aims to study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of OA. Patients with OA will receive intravenous infusion and intraarticular injection of UC-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
92
cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Medical Surgical Associates Center
St John's, Antigua and Barbuda
RECRUITINGAthens Beverly Hills Medical Group
Glyfada, Athens, Greece
RECRUITINGSafety (adverse events)
Clinical monitoring of possible adverse events or complications
Time frame: Four year follow-up
Efficacy: Single Assessment Numeric Evaluation Score (SANE)
ranging from 0 to 100%
Time frame: Four year follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.